View Future GrowthStem Cells Spin 과거 순이익 실적과거 기준 점검 0/6Stem Cells Spin 의 수입은 연평균 -49.5%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 13.3%의 비율로 증가했습니다. 매출은 연평균 30.4%의 비율로 감소해 왔습니다.핵심 정보-49.46%순이익 성장률-50.16%주당순이익(EPS) 성장률Biotechs 산업 성장률56.32%매출 성장률-30.44%자기자본이익률-8.88%순이익률-846.47%다음 순이익 업데이트14 Aug 2026최근 과거 실적 업데이트공고 • Nov 12Stem Cells Spin S.A. to Report Q3, 2025 Results on Nov 14, 2025Stem Cells Spin S.A. announced that they will report Q3, 2025 results on Nov 14, 2025Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: zł133.5k (loss widened 3.9% from 1Q 2024).Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł130.7k (down zł148.8k from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł128.5k (loss widened 64% from 1Q 2023).Reported Earnings • Feb 16Full year 2023 earnings released: zł0.004 loss per share (vs zł0.001 profit in FY 2022)Full year 2023 results: zł0.004 loss per share (down from zł0.001 profit in FY 2022). Net loss: zł154.0k (down zł180.6k from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.공고 • Jan 23+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Stem Cells Spin S.A. announced that they will report fiscal year 2023 final results on Apr 30, 2024모든 업데이트 보기Recent updates공고 • Jun 01Stem Cells Spin S.A., Annual General Meeting, Jun 25, 2026Stem Cells Spin S.A., Annual General Meeting, Jun 25, 2026, at 09:30 Central European Standard Time.New Risk • May 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł107k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł107k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (zł65k revenue, or US$18k). Market cap is less than US$10m (zł14.9m market cap, or US$4.10m).New Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł86k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł86k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (zł66k revenue, or US$18k). Market cap is less than US$10m (zł16.5m market cap, or US$4.52m).공고 • Nov 12Stem Cells Spin S.A. to Report Q3, 2025 Results on Nov 14, 2025Stem Cells Spin S.A. announced that they will report Q3, 2025 results on Nov 14, 2025New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (zł58k revenue, or US$15k). Market cap is less than US$10m (zł7.77m market cap, or US$2.07m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-zł71k).Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: zł133.5k (loss widened 3.9% from 1Q 2024).New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł7.44m market cap, or US$1.94m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).New Risk • Feb 21New major risk - Revenue and earnings growthEarnings have declined by 0.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł8.76m market cap, or US$2.20m).Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł130.7k (down zł148.8k from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.공고 • Jun 05Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024.Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł128.5k (loss widened 64% from 1Q 2023).Reported Earnings • Feb 16Full year 2023 earnings released: zł0.004 loss per share (vs zł0.001 profit in FY 2022)Full year 2023 results: zł0.004 loss per share (down from zł0.001 profit in FY 2022). Net loss: zł154.0k (down zł180.6k from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.공고 • Jan 23+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Stem Cells Spin S.A. announced that they will report fiscal year 2023 final results on Apr 30, 2024Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 22% to zł0.43. The fair value is estimated to be zł0.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Earnings per share has declined by 41%.Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: zł99.8k (loss widened 51% from 3Q 2022).Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Net income: zł18.1k (up zł118.4k from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.공고 • Jun 04Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023, at 09:00 Central European Standard Time.Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Net loss: zł78.4k (down 147% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 18Full year 2022 earnings released: EPS: zł0.001 (vs zł0.003 loss in FY 2021)Full year 2022 results: EPS: zł0.001 (up from zł0.003 loss in FY 2021). Revenue: zł248.4k (down 53% from FY 2021). Net income: zł26.7k (up zł154.1k from FY 2021). Profit margin: 11% (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.공고 • Jan 31+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2022 Results on May 31, 2023Stem Cells Spin S.A. announced that they will report fiscal year 2022 results on May 31, 2023공고 • Jun 07Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022, at 10:00 Central European Standard Time.Reported Earnings • May 22First quarter 2022 earnings releasedFirst quarter 2022 results: Net income: zł167.4k (down 2.2% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: zł0.002 loss per share (down from zł0 in FY 2020). Net loss: zł99.5k (down zł105.9k from profit in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.공고 • Feb 02+ 3 more updatesStem Cells Spin S.A. to Report Q4, 2022 Results on Feb 14, 2022Stem Cells Spin S.A. announced that they will report Q4, 2022 results on Feb 14, 2022Reported Earnings • May 23First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł234.6k (up zł215.6k from 1Q 2020). Net income: zł171.2k (up zł261.9k from 1Q 2020). Profit margin: 73% (up from net loss in 1Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.Is New 90 Day High Low • Mar 09New 90-day low: zł1.13The company is down 25% from its price of zł1.50 on 09 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.Reported Earnings • Feb 18Full year 2020 earnings released: zł0.001 loss per share (vs zł0.017 loss in FY 2019)Full year 2020 results: Net loss: zł51.3k (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.공고 • Feb 02Stem Cells Spin S.A. to Report Fiscal Year 2020 Final Results on May 31, 2021Stem Cells Spin S.A. announced that they will report fiscal year 2020 final results on May 31, 2021공고 • Feb 01+ 3 more updatesStem Cells Spin S.A. to Report Q3, 2021 Results on Nov 15, 2021Stem Cells Spin S.A. announced that they will report Q3, 2021 results on Nov 15, 2021Is New 90 Day High Low • Dec 10New 90-day high: zł1.88The company is up 32% from its price of zł1.42 on 11 September 2020. The Polish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.Is New 90 Day High Low • Sep 29New 90-day high: zł1.70The company is up 75% from its price of zł0.97 on 26 June 2020. The Polish market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 62% over the same period.매출 및 비용 세부 내역Stem Cells Spin가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이WSE:SCS 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-10031 Dec 250-10030 Sep 250-10030 Jun 250-10031 Mar 250-10031 Dec 240-10030 Sep 24000030 Jun 24000031 Mar 24000031 Dec 23000030 Sep 23000030 Jun 23000031 Mar 23000031 Dec 22000030 Sep 22000030 Jun 22000031 Mar 22000031 Dec 21100030 Sep 21100030 Jun 21000031 Mar 21000031 Dec 20000030 Sep 20000030 Jun 20000031 Mar 201-10031 Dec 191-10030 Sep 191-10030 Jun 190-10031 Mar 190-10031 Dec 181-10030 Sep 18100030 Jun 18100031 Mar 18100031 Dec 17000030 Sep 17100030 Jun 17100031 Mar 17100031 Dec 16100030 Sep 16111030 Jun 16211031 Mar 16211031 Dec 15211030 Sep 151010양질의 수익: SCS 은(는) 현재 수익성이 없습니다.이익 마진 증가: SCS는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: SCS은 수익성이 없으며 지난 5년 동안 손실이 연평균 49.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 SCS의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: SCS은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(1.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: SCS는 현재 수익성이 없으므로 자본 수익률이 음수(-8.88%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/14 11:40종가2026/07/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Stem Cells Spin S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Nov 12Stem Cells Spin S.A. to Report Q3, 2025 Results on Nov 14, 2025Stem Cells Spin S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: zł133.5k (loss widened 3.9% from 1Q 2024).
Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł130.7k (down zł148.8k from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł128.5k (loss widened 64% from 1Q 2023).
Reported Earnings • Feb 16Full year 2023 earnings released: zł0.004 loss per share (vs zł0.001 profit in FY 2022)Full year 2023 results: zł0.004 loss per share (down from zł0.001 profit in FY 2022). Net loss: zł154.0k (down zł180.6k from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.
공고 • Jan 23+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Stem Cells Spin S.A. announced that they will report fiscal year 2023 final results on Apr 30, 2024
공고 • Jun 01Stem Cells Spin S.A., Annual General Meeting, Jun 25, 2026Stem Cells Spin S.A., Annual General Meeting, Jun 25, 2026, at 09:30 Central European Standard Time.
New Risk • May 29New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł107k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł107k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (zł65k revenue, or US$18k). Market cap is less than US$10m (zł14.9m market cap, or US$4.10m).
New Risk • May 18New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł86k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł86k free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 52% per year over the past 5 years. Revenue is less than US$1m (zł66k revenue, or US$18k). Market cap is less than US$10m (zł16.5m market cap, or US$4.52m).
공고 • Nov 12Stem Cells Spin S.A. to Report Q3, 2025 Results on Nov 14, 2025Stem Cells Spin S.A. announced that they will report Q3, 2025 results on Nov 14, 2025
New Risk • May 21New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Revenue is less than US$1m (zł58k revenue, or US$15k). Market cap is less than US$10m (zł7.77m market cap, or US$2.07m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-zł71k).
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: zł133.5k (loss widened 3.9% from 1Q 2024).
New Risk • Mar 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł7.44m market cap, or US$1.94m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
New Risk • Feb 21New major risk - Revenue and earnings growthEarnings have declined by 0.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.5% per year over the past 5 years. Revenue is less than US$1m (zł54k revenue, or US$14k). Market cap is less than US$10m (zł8.76m market cap, or US$2.20m).
Reported Earnings • Aug 18Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: zł130.7k (down zł148.8k from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
공고 • Jun 05Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024Stem Cells Spin S.A., Annual General Meeting, Jun 27, 2024.
Reported Earnings • May 20First quarter 2024 earnings releasedFirst quarter 2024 results: Net loss: zł128.5k (loss widened 64% from 1Q 2023).
Reported Earnings • Feb 16Full year 2023 earnings released: zł0.004 loss per share (vs zł0.001 profit in FY 2022)Full year 2023 results: zł0.004 loss per share (down from zł0.001 profit in FY 2022). Net loss: zł154.0k (down zł180.6k from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.
공고 • Jan 23+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2023 Final Results on Apr 30, 2024Stem Cells Spin S.A. announced that they will report fiscal year 2023 final results on Apr 30, 2024
Buy Or Sell Opportunity • Jan 22Now 20% undervaluedOver the last 90 days, the stock has risen 22% to zł0.43. The fair value is estimated to be zł0.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.6% over the last 3 years. Earnings per share has declined by 41%.
Reported Earnings • Nov 19Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: zł99.8k (loss widened 51% from 3Q 2022).
Reported Earnings • Aug 20Second quarter 2023 earnings releasedSecond quarter 2023 results: Net income: zł18.1k (up zł118.4k from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
공고 • Jun 04Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023Stem Cells Spin S.A., Annual General Meeting, Jun 29, 2023, at 09:00 Central European Standard Time.
Reported Earnings • May 21First quarter 2023 earnings releasedFirst quarter 2023 results: Net loss: zł78.4k (down 147% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 18Full year 2022 earnings released: EPS: zł0.001 (vs zł0.003 loss in FY 2021)Full year 2022 results: EPS: zł0.001 (up from zł0.003 loss in FY 2021). Revenue: zł248.4k (down 53% from FY 2021). Net income: zł26.7k (up zł154.1k from FY 2021). Profit margin: 11% (up from net loss in FY 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
공고 • Jan 31+ 4 more updatesStem Cells Spin S.A. to Report Fiscal Year 2022 Results on May 31, 2023Stem Cells Spin S.A. announced that they will report fiscal year 2022 results on May 31, 2023
공고 • Jun 07Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022Stem Cells Spin S.A., Annual General Meeting, Jun 28, 2022, at 10:00 Central European Standard Time.
Reported Earnings • May 22First quarter 2022 earnings releasedFirst quarter 2022 results: Net income: zł167.4k (down 2.2% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 16Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: zł0.002 loss per share (down from zł0 in FY 2020). Net loss: zł99.5k (down zł105.9k from profit in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 19% per year, which means it is significantly lagging earnings growth.
공고 • Feb 02+ 3 more updatesStem Cells Spin S.A. to Report Q4, 2022 Results on Feb 14, 2022Stem Cells Spin S.A. announced that they will report Q4, 2022 results on Feb 14, 2022
Reported Earnings • May 23First quarter 2021 earnings releasedThe company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: zł234.6k (up zł215.6k from 1Q 2020). Net income: zł171.2k (up zł261.9k from 1Q 2020). Profit margin: 73% (up from net loss in 1Q 2020). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has increased by 35% per year, which means it is well ahead of earnings.
Is New 90 Day High Low • Mar 09New 90-day low: zł1.13The company is down 25% from its price of zł1.50 on 09 December 2020. The Polish market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is flat over the same period.
Reported Earnings • Feb 18Full year 2020 earnings released: zł0.001 loss per share (vs zł0.017 loss in FY 2019)Full year 2020 results: Net loss: zł51.3k (loss narrowed 93% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings.
공고 • Feb 02Stem Cells Spin S.A. to Report Fiscal Year 2020 Final Results on May 31, 2021Stem Cells Spin S.A. announced that they will report fiscal year 2020 final results on May 31, 2021
공고 • Feb 01+ 3 more updatesStem Cells Spin S.A. to Report Q3, 2021 Results on Nov 15, 2021Stem Cells Spin S.A. announced that they will report Q3, 2021 results on Nov 15, 2021
Is New 90 Day High Low • Dec 10New 90-day high: zł1.88The company is up 32% from its price of zł1.42 on 11 September 2020. The Polish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Sep 29New 90-day high: zł1.70The company is up 75% from its price of zł0.97 on 26 June 2020. The Polish market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 62% over the same period.